Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT03331731 |
| Title | A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma (PLIMATH) |
| Acronym | PLIMATH |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Peter MacCallum Cancer Centre, Australia |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | NZL | AUS |